EGFR and lung carcinoma: EGFR-dedicated therapies with TKIs, such as afatinib and erlotinib, are currently used as first- and second-line lung cancer treatments [47], improving objective response rates and progression-free survival compared to cytotoxic therapy for patients with mutated EGFR [48,49,50].